SCHEMBL6883115

SCHEMBL6883115

O=C(O)c1cnc(N2CCNCC2)nc1Oc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.47
ALDH1A1 P00352 10/20 0.46
CYP1A2 P05177 10/20 0.46
CASP1 P29466 9/20 0.46
CASP7 P55210 9/20 0.46
CYP3A4 P08684 9/20 0.46
HSD17B10 Q99714 8/20 0.46
CYP2C9 P11712 8/20 0.46
MAPK1 P28482 4/20 0.44
HRH3 Q9Y5N1 1/20 0.43
HTR1A P08908 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HIF1A Q16665 7/20 0.42
USP2 O75604 7/20 0.42
CYP2C19 P33261 6/20 0.42
TP53 P04637 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperazine SCHEMBL6883092 0.99 SCN9A (0.46) SCN9AALDH1A1CYP1A2CASP1CASP7
Methylpiperazine SCHEMBL6878843 0.92 HRH4 (0.44) SCN9AALDH1A1CYP1A2CASP1CASP7
SCHEMBL16671809 0.90 MEN1 (0.52) SCN9AALDH1A1CYP1A2CASP1CASP7
SCHEMBL6883095 0.87 CASP1 (0.43) SCN9AALDH1A1CYP1A2CASP1CASP7
SCHEMBL6872292 0.86 HRH4 (0.49) SCN9AALDH1A1CYP1A2CASP1CASP7
Methylpiperazine SCHEMBL6881276 0.81 HRH4 (0.51) ALDH1A1CYP1A2CASP1CASP7CYP3A4
SCHEMBL16676723 0.81 BTK (0.48) SCN9AALDH1A1CYP1A2CASP1CASP7
SCHEMBL5800464 0.81 LCK (0.45) ALDH1A1CYP1A2CASP1CASP7CYP3A4
SCHEMBL4112334 0.80 ALDH1A1 (0.54) ALDH1A1CYP1A2CASP1CASP7CYP3A4
Hydrochloric Acid SCHEMBL16670652 0.80 BTK (0.48) SCN9ACYP1A2MEN1KMT2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US claimed
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
EP-1339698-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-03 EP disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed
WO-2002042280-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 SCN9A 1166/4885ALDH1A1 1117/4885CYP1A2 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.